Study details
Enrolling now
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
HiberCell, Inc.
NCT IDNCT06234605ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
80
Study length
about 3.6 years
Ages
18+
Locations
20 sites in AZ, CA, CO +11
What this study is about
This trial is testing a treatment combination of HC-7366 and belzutifan in people with kidney cancer. The goal is to find the highest dose that can be safely used, and see if it works.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Belzutifan
- 2.Take HC-7366
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
belzutifan
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Determination of MTD and RP2D (combination cohorts only)
Body systems
Oncology